Delcath Systems Inc. has published a comprehensive subgroup analysis of its Phase 3 FOCUS study, evaluating the HEPZATO KIT—its U.S. Food and Drug Administration–approved melphalan/Hepatic Delivery System—for unresectable metastatic uveal melanoma. The data, now available in the Journal of Cancer Research and Clinical Oncology, provide new insights into how baseline disease characteristics like hepatic tumor burden and LDH levels influence patient outcomes. The study affirms the consistency of treatment efficacy across age, sex, region, and prior treatment status, while identifying clear survival advantages in select subgroups. These findings carry major implications for earlier treatment initiation, patient selection, and future trial design.

What the new data reveal about tumor burden and timing of treatment

One of the strongest patterns to emerge from the subgroup analysis relates to baseline liver tumor burden. Patients whose hepatic tumor burden fell below the median at baseline achieved an objective response rate of 51.1 percent, compared to just 22.2 percent in patients with tumor burden above the median. Median progression-free survival for the lower-burden cohort was 11.3 months, nearly double the 5.8 months seen in the higher-burden group. Median overall survival was also significantly longer at 26.7 months versus 15.4 months, indicating that tumor volume at the start of treatment remains one of the most important prognostic factors

These findings support a clinical strategy of earlier treatment initiation with HEPZATO KIT in patients with unresectable metastatic uveal melanoma, especially those with modest hepatic tumor load. In settings where access to liver-directed therapies is delayed due to referral bottlenecks, insurance approvals, or treatment sequencing with systemic agents, this data may compel oncologists and multidisciplinary tumor boards to re-evaluate timelines.

LDH levels and liver involvement percentage also shape survival outcomes

The analysis also found that baseline LDH levels, a marker of tumor aggressiveness and metabolic stress, strongly correlated with overall survival. Patients with low or normal LDH values had a median overall survival of 23.5 months compared to 15.3 months in those with elevated LDH levels. Similarly, patients with 1–25 percent liver involvement lived a median 22.4 months versus 16.9 months for those with greater hepatic involvement

Though LDH has long been associated with poorer outcomes in metastatic uveal melanoma, its stratification within a liver-directed therapy trial confirms its relevance even in local-regional treatment contexts. This could influence patient counseling, reimbursement prioritization, and trial enrichment strategies for future liver-targeted drug-device platforms.

Efficacy remains consistent across other demographic subgroups

Importantly, the FOCUS subgroup analyses showed consistent efficacy of HEPZATO KIT across multiple demographic and clinical subgroups. Neither age, sex, geographic region (United States vs. Europe), presence of extrahepatic disease, nor the number of prior therapies significantly impacted treatment outcomes in terms of ORR, PFS, or OS. This suggests that the melphalan/Hepatic Delivery System is broadly applicable across a wide range of patients with metastatic uveal melanoma, irrespective of prior exposure to immune checkpoint inhibitors or systemic chemotherapy.

The fact that outcomes did not vary significantly based on prior therapy status is particularly notable in a disease setting where sequencing of liver-directed and systemic treatments remains an area of clinical uncertainty.

Later-cycle responders reinforce the need for treatment completion

Delcath’s analysis also tracked when tumor responses occurred across the six-cycle treatment protocol. Of the 33 patients who achieved a complete or partial response, over half (57.6 percent) responded during the first or second treatment cycle. However, nearly one-third of responses emerged only during cycles four through six, underscoring the need for treatment persistence even in the absence of early radiographic improvement.

This insight carries operational and economic weight. It cautions against premature discontinuation in patients not exhibiting immediate response and provides justification for payers and clinicians to support full completion of the six-cycle regimen. In a therapeutic area where options are scarce and the cost of late intervention is high, these response kinetics offer important treatment planning data.

What differentiates HEPZATO KIT in an otherwise limited therapeutic space

Metastatic uveal melanoma remains an orphan indication with few approved therapies. Tebentafusp, a bispecific T cell engager, is approved only for HLA-A*02:01-positive patients, limiting its use to an estimated 45 percent of the mUM population. By contrast, HEPZATO KIT is the only FDA-approved liver-directed therapy for metastatic uveal melanoma and is not limited by genetic subtype or HLA status.

This broad applicability is paired with a unique therapeutic mechanism: targeted high-dose melphalan delivery via percutaneous hepatic perfusion, with filtration technology to minimize systemic exposure. The procedure requires multidisciplinary care, including interventional radiology, anesthesiology, and perfusion services, but offers patients a chance at durable liver control without systemic toxicity typical of conventional chemotherapy.

Given that up to 90 percent of metastatic uveal melanoma cases involve the liver and that liver failure is a leading cause of mortality in this population, the rationale for a hepatic-first approach is biologically grounded. Delcath’s platform addresses that unmet need with greater precision than any existing systemic therapy.

Study design amendments and trial integrity

Originally initiated as a randomized trial comparing melphalan/HDS with best alternative care, the FOCUS study was amended to a single-arm design due to recruitment challenges and patient reluctance to receive systemic therapies with limited efficacy. To maintain regulatory and scientific rigor, Delcath conducted a historical meta-analysis of 16 studies comprising 476 patients to establish a benchmark for expected outcomes. This benchmark underpinned the FDA approval of HEPZATO KIT in 2023.

Though single-arm designs carry interpretive limitations, the trial incorporated oversight by an Independent Review Committee and independent data safety monitoring board. Tumor responses were adjudicated by central review using RECIST 1.1, adding objectivity to the efficacy data. This careful study design has drawn approval from regulators while also demonstrating real-world feasibility of the HEPZATO KIT procedure across 23 sites in the United States and Europe.

Operational and scalability considerations remain a key challenge

Despite the promising efficacy and consistent safety profile, questions remain about access, adoption, and long-term scalability. HEPZATO KIT requires significant procedural infrastructure, including general anesthesia, double-balloon catheter placement, extracorporeal filtration, and a trained perfusionist team. These requirements may limit widespread adoption outside of high-volume cancer centers or interventional oncology programs.

Moreover, the long-term durability of responses in real-world settings and the feasibility of repeated cycles in patients with borderline performance status remain to be fully assessed. While the FOCUS trial reported no treatment-related deaths and a manageable safety profile characterized mainly by hematological toxicity, ongoing pharmacovigilance will be critical.

Health technology assessment bodies may also evaluate cost-effectiveness in light of the procedural complexity, especially in countries where systemic immunotherapies dominate due to convenience and institutional familiarity.

Looking ahead: broader potential for liver-directed oncology

Delcath Systems Inc. may seek to expand its interventional oncology platform into other tumor types with dominant liver metastasis profiles, such as colorectal cancer, cholangiocarcinoma, or certain neuroendocrine tumors. The approval of HEPZATO KIT opens the door to new clinical development programs leveraging the same device-drug combination or variants thereof.

Future trials may also use the subgroup data from FOCUS to refine inclusion criteria, stratify randomization, or personalize treatment sequencing. There is potential for integration with systemic therapies in combination regimens or post-progression salvage settings.

The publication of this subgroup analysis marks not just an academic milestone but also a strategic inflection point in the evolving treatment paradigm for metastatic uveal melanoma.

  Delcath Systems, FDA approval, HEPZATO KIT, interventional oncology, LDH biomarker, liver cancer, liver-directed therapy, melphalan, metastatic uveal melanoma, Phase 3 FOCUS study